Back to Peptides
PE-22-28
Pain Management & Neuroactive PeptidesPE-22-28 is a short neuropeptide with demonstrated effects in cognitive enhancement, neuroprotection, and mood stabilization. It acts by regulating gene expression and protein synthesis in neurons and has shown positive outcomes in memory, focus, and anxiety models. It is typically administered via subcutaneous injection and has a favorable safety profile in animals.
Reconstitute
3 mL BAC + 10mg vial
33 mcg/unit
Daily Range
200–600 mcg Subcutaneous (SQ)
Daily
Standard Dose
400 mcg
Cycle
4–8 weeks
then reassess
PE-22-28cognitive enhancementneurotrophin peptidememory peptideneuroprotection
Dosing & Reconstitution Guide
Animal studies typically used 100–200 μg/kg intraperitoneally. No human dosing studies have been conducted.
Standard / Gradual Approach
10mg VialstandardPhaseDoseVolume
Weeks 1–250 µg1.5 units (0.015 mL)
Weeks 3–4100 µg3 units (0.03 mL)
Weeks 5–8100 µg3 units (0.03 mL)
Weeks 9–12 (Optional)150 µg4.5 units (0.045 mL)
Weeks 13–16 (Optional)200 µg6 units (0.06 mL)
Protocol Summary
Subcutaneous (SQ): Daily · Dose range 200–600 mcg with gradual titration
Cycle Length: 4–8 weeks typical; reassess before extending
Frequency & Cycling
SubQ Injection
Recommended cycle: 4–6 weeks of daily use. Can be repeated every 2–3 months with a 2–4 week rest period.
🧪 Quick Start
Vial Size
10 mg
BAC Water
3 mL
Concentration
3.33 mcg/unit
Starting Dose
50 µg (1.5 units (0.015 mL))
Maintenance Dose
200 µg (6 units (0.06 mL))
Potential Benefits & Use Cases
PE-22-28 is an experimental research compound not approved for clinical or therapeutic use.
Produces rapid antidepressant effects within 4 days in rodent models (preclinical)
Increases hippocampal neurogenesis, synaptogenesis markers (PSD-95), dendritic spine density, and BDNF expression (preclinical)
Preserves dopaminergic neurons and reduces motor deficits in stroke models (preclinical)
Shows high selectivity with no effects on cardiac, metabolic, or pain pathways (preclinical)
Clinical data Strong preclinical Limited data
Mechanism of Action
→Enhances gene expression related to neuroplasticity and memory
→Modulates protein synthesis in hippocampal neurons
→Stimulates neurotrophin (e.g. BDNF) production in cortical brain regions
→Protects neurons from oxidative damage and apoptosis
Lifestyle & Optimization
timing
Consistent dosing schedule.
diet
Omega-3s, antioxidants, and B vitamins.
exercise
Regular exercise for BDNF enhancement. Cognitive training.
sleep
Consistent sleep schedule (7–9 hours). Stress management.
Peptide Research & Preclinical Studies
Evidence-Based Research Findings
Study TitleType
Side Effects & Safety
Common Side Effects
• Mild GI discomfort, nausea, headache — all very uncommon (preclinical extrapolation)
Contraindications & Warnings
• Theoretical risk of sedation or blunted motivation with overdosing (animal data)
🧮 Dose Calculator
Concentration
33.3
mcg/unit
Draw Volume
15
units (0.150 mL)
For a 500 mcg dose, draw 15 units on a U-100 insulin syringe
🧬
Bioavailability & Absorption
SubQ Injection
High systemic and CNS access via subcutaneous route
Oral Administration
Low bioavailability due to GI degradation
Intranasal
Capable of nose-to-brain targeting but less common
Half-Life
Approximately 6 hours
Degradation
Metabolized primarily in liver and neural tissues
Tissue Specificity
Targets hippocampus, cortex, and brain regions related to cognition and neuroinflammation
⚗️
Peptide Details
Molecular Weight
200.25
Formula
C10H16N2O3
Sequence
Lys-Gly-Asn
⚖️
Legal Status & Regulatory
RegionStatus
FDANot Approved
EUNot Approved
AustraliaNot Approved
CanadaNot Approved
Storage Instructions
Lyophilized (Powder)
freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); protect from light
Reconstituted (Mixed)
Refrigerate at 2–8 °C (35.6–46.4 °F); use within 4 weeks for optimal potency